Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for ...

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

Curium received FDA approval for BEXLUTRY™, a lutetium Lu 177 dotatate injection targeting SSTR-positive gastroenteropancreatic neuroendocrine tumors in adults, marking its expansion into oncology therapeutics with a full diagnosis-to-therapy offering.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now expect a strong new competitor with FDA approval for a lutetium-based NET therapy backed by a vertically integrated manufacturer. This approval opens a reliable supply path and new demand signals at cancer treatment sites for therapies targeting neuroendocrine tumors.

◆ Coverage

1 source · 15 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalradioligand-therapyoncologyNETCurium